BioCentury | Sep 14, 2019
Finance

Mark Schoenebaum: Setting the gold standard

...passing, too terribly soon, I have thought many times of a quote often attributed to Maya...
BioCentury | Aug 12, 2019
Company News

Management tracks: Bailey leaving GSK; plus HHS drug pricing adviser to depart and more

...U.S. Pharmaceuticals at GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) at year end. He will be replaced by Maya...
BioCentury | Sep 14, 2017
Targets & Mechanisms

Platelets YAP at cancer

...MD Anderson Cancer Center Vivace Therapeutics Large tumor suppressor homolog 1 (LATS1) LATS large tumor suppressor homolog 2 (LATS2) MST1/2-antagonizing for YAP activation (MAYA) Yes-associated...
BioCentury | Feb 2, 2017
Distillery Therapeutics

Cancer

...cancer Cell culture and mouse studies suggest inhibiting ROR1 or the long non-coding RNA (lncRNA) MAYA...
...ROR1 knockout or MAYA knockdown decreased proliferation, migration and invasiveness compared with normal ROR1 and MAYA...
...or a locked nucleic acid (LNA) targeting MAYA decreased metastatic tumor burden compared with normal MAYA...
BioCentury | Oct 31, 2013
Distillery Techniques

Technology: Markers

...application filed; licensing details available from The University of Chicago and the University of Pittsburgh Herazo-Maya...
BioCentury | May 19, 2011
Distillery Therapeutics

Indication: Autoimmune disease

...published online May 8, 2011; doi:10.1038/nature09982 Contact: Maya Saleh, McGill University, Montreal, Quebec, Canada e-mail: maya.saleh@mcgill.ca BC...
BioCentury | Jul 23, 2009
Distillery Therapeutics

Indication: Various

...June 18, 2009; doi:10.1016/j.immuni.2009.04.011 Contact: Maya Saleh, McGill University Life Sciences Complex, Quebec, Canada e-mail: maya.saleh@mcgill.ca...
BioCentury | Jan 4, 1999
Company News

Xenova other research news

...with El Colegio de la Frontera Sur (San Cristobal de Las Casas, Mexico) and local Maya...
Items per page:
1 - 8 of 8